GlassScriptPhysician profile
Piotr Stola
NPI 1942248604
$9,196.52
in general payments reported to CMS, 2019-2025
45 companies · $2,333 in 2025
The $2,333 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $500 · 2021: $1,129 · 2022: $1,368 · 2023: $1,174 · 2024: $1,860 · 2025: $2,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,360 · Travel and Lodging: $828 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,359.54 |
| Travel and Lodging | $827.72 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,210.58 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $783.24 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $777.17 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Jazz Pharmaceuticals INC. | $688.05 | 2019-2024 | Xywav |
| Grifols USA, LLC | $542.45 | 2019-2025 | Prolastin-C Liquid |
| Cook Incorporated | $489.77 | 2024 | Melker |
| Mylan Specialty L.P. | $461.43 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.16 | 2019-2025 | Jascayd |
| Insmed, INC. | $368.23 | 2021-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $341.03 | 2019-2025 | Opsumit, Uptravi |
| Philips North America LLC | $291.56 | 2021-2024 | (Ak6) Vest Therapy |
| United Therapeutics Corporation | $278.73 | 2019-2025 | Tyvaso, Tyvaso |
| Baxter Healthcare | $214.41 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Ethicon INC. | $194.61 | 2023-2025 | Monarch Platform |
| Harmony Biosciences LLC | $175.97 | 2020-2025 | Wakix |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $151.27 | 2021-2025 | Smartvest |
| Inari Medical, INC. | $142.68 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $137.74 | 2023-2025 | Lumryz |
| Genentech USA, INC. | $126.56 | 2019-2023 | Xolair |
| Tempus Ai, INC | $115.29 | 2025 | Xt Cdx |
| Regeneron Healthcare Solutions, INC. | $101.75 | 2021-2024 | Dupixent |
| Viatris Specialty LLC | $93.18 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $85.13 | 2020-2022 | |
| Axsome Therapeutics, INC. | $82.16 | 2025 | Sunosi |
| Sunovion Pharmaceuticals INC. | $71.43 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $71.07 | 2022-2023 | Acthar |
| Zoll Respicardia, INC. | $68.22 | 2023-2025 | Remede System |
| Abbott Laboratories | $65.73 | 2019-2022 | |
| Verona Pharma, INC. | $65.64 | 2025 | Ohtuvayre |
| Allergan, INC. | $62.45 | 2019-2020 | |
| Chiesi USA, INC. | $55.54 | 2021 | |
| Merck Sharp & Dohme LLC | $52.82 | 2019-2024 | Winrevair |
| Genzyme Corporation | $50.97 | 2022-2025 | |
| Gilead Sciences, INC. | $41.72 | 2019 | |
| Lilly USA, LLC | $40.47 | 2025 | Zepbound |
| Paratek Pharmaceuticals, INC. | $34.21 | 2021-2022 | |
| Amgen INC. | $33.98 | 2021-2022 | |
| Itamar Medical INC | $33.34 | 2023-2025 | Watchpatone |
| Circassia INC. | $33.33 | 2019 | |
| Advanced Respiratory, INC | $26.89 | 2020 | |
| Ani Pharmaceuticals, INC. | $21.44 | 2025 | Purified Cortrophin Gel |
| Cook Medical LLC | $17.93 | 2024 | Blue Rhino |
| Shire North American Group INC | $17.58 | 2019 | |
| Apria Healthcare LLC | $15.96 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Piotr Stola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.